Data regarding possible vaccinations against Sars-Cov-2 for children between 2-5 years will be ready in March.
Moderna made it known today, underlining that the ongoing trials "are in the pipeline".
If the results are positive, an application for approval will be presented to the regulatory bodies.
As early as December - explains the company - Moderna began studying the possibility of using lower doses of the vaccine for children between 6-11 years and adolescents between 12-17 years.
Trials are underway.
The case of the unavailable antibiotic, Aifa advises against it
